Alembic Pharma's JV Aleor Dermaceuticals gets tentative nod from USFDA for testosterone gel
Aleor Dermaceuticals has received tentative approval from the US Food and Drug Administration (USFDA) for its abbreviated new drug application (ANDA) for Testosterone Gel, 1.62 per cent (20.25 mg/1.25 gm actuation), Alembic Pharmaceuticals said in a regulatory filing.
Source: The Economic Times Healthcare and Biotech News - Category: Pharmaceuticals Source Type: news
More News: AndroGel | Biotechnology | Dermatology | Food and Drug Administration (FDA) | New Drug Applications | Pharmaceuticals